FilingSEC EDGAR8-K
Tectonic Therapeutic Announces Positive Phase 1a Results for TX2100 and FDA Fast Track Designation
· SEC accepted
StagePhase 1a completed
Filing content
The company reported favorable safety and PK results from its Phase 1a trial of TX2100 and received FDA Fast Track designation for the treatment of HHT.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…